A Phase 2/3 interventional study of Afimetoran and Placebo in Cutaneous Lupus Erythematosus (CLE) and Systematic Lupus Erythematosus, sponsored by Beeline Medicines Corporation. Recruiting at 3 sites in United States. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Beeline Medicines Corporation · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Lupus Erythematosus, Cutaneous with a site in United States — 10 open to participants now, 16 under way, 7 of them phase 3. Lupus Erythematosus, Cutaneous · United States.
Among the 39 studies in Lupus Erythematosus, Cutaneous with a site in United States, this one is the 4th largest by planned enrollment of the 34 interventional ones that give a count, is one of 5 that started in 2026, is one of 2 in phase 2/3, reaches primary completion later than 13 of the 15 other live ones, and was the 39th registered.
67 studies on the registry are indexed under Lupus Erythematosus, Cutaneous; 18 are open to participants now.
Browse Lupus Erythematosus, Cutaneous studies →10 of the 39 studies in Lupus Erythematosus, Cutaneous with a site in United States are open now. Recruiting first, the newest first:
EMD Serono Research & Development Institute, Inc. · Sites in United States
Ages 18–76
Victoria Werth · Sites in United States
Ages 18+
EMD Serono Research & Development Institute, Inc. · Sites in United States, Australia, Belgium and 17 more countries
Ages 18–75
EMD Serono Research & Development Institute, Inc. · Sites in United States, Australia, Belgium and 17 more countries
Ages 18–75
DualityBio Inc. · Sites in United States, Australia
Ages 18–70 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Lupus Erythematosus, Cutaneous studies recruiting now, 4 (33%) set no upper age limit and 7 (58%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 18 · Phase 3 7
First in 2006; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 390 is above the median of 32 across 57 interventional studies indexed under Lupus Erythematosus, Cutaneous.
Median enrollment 46 across the 34 interventional studies, 77 across the 5 observational. Of the 23 that completed or were terminated, 11 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 39 have an industry lead sponsor. The 10 most frequent:
Beeline Medicines Corporation is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Beeline Medicines Corporation has 1 study filed under Lupus Erythematosus, Cutaneous — fewer than ten, so there is no comparison to draw.
3 of the studies in Lupus Erythematosus, Cutaneous with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07260877Ventus Therapeutics U.S., Inc.A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus | 2026-12 |
| NCT06625671DualityBio Inc.A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants | 2027-06-30 |
| NCT06661213Northwestern UniversityTapinarof for Cutaneous Lupus Erythematosus | 2027-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 39 studies in Lupus Erythematosus, Cutaneous with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is evaluating whether afimetoran, an investigational oral medicine that blocks toll-like receptors 7 and 8 (TLR7/TLR8), can improve skin disease in adults with active cutaneous lupus erythematosus (CLE), with or without systemic lupus, whose disease has not responded to or who cannot tolerate antimalarial therapy. Participants are assigned by chance to receive afimetoran or a matching placebo capsule once daily for 24 weeks, in addition to their existing standard lupus care. Neither participants nor study staff know which treatment is given.
The study is run in two stages under a single protocol. Stage 1 compares two doses of afimetoran with placebo to select the dose. Stage 2 compares the selected afimetoran dose with placebo to confirm efficacy and safety. After the 24-week placebo-controlled period, all participants receive afimetoran for a further 28 weeks, for a total of 52 weeks of treatment. The main measures of benefit are the change in the CLASI-A skin activity score and the proportion of participants achieving a 70% improvement in that score at Week 24.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Afimetoran
Drug: Afimetoran
Drug: Placebo
Afimetoran (BLN-256) oral capsule, once daily
Also known as: BLN-256
Placebo (capsule matched to afimetoran), once daily
Percent change from baseline in CLASI-A total score
Demonstrates efficacy of afimetoran vs placebo based on CLASI-A change in participants with active CLE with or without systemic manifestations
Time frame: Baseline to Week 24
Proportion of participants achieving a CLASI-70 response (≥70% decrease from baseline in CLASI-A total score)
To demonstrate the superiority of afimetoran compared with placebo based on CLASI-70 response in participants with active CLE with or without systemic manifestations
Time frame: Week 24
Proportion of Participants achieving a CLASI-70 response
Proportion of participants achieving a Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) response of at least 70% (CLASI-70). Participants achieve a CLASI-70 response if they have a ≥70% decrease from baseline in CLASI-A total score. CLASI-A scores range from 0 to 70, with higher scores indicating greater cutaneous lupus disease activity.
Time frame: Weeks 12, 16, and 24
Proportion of participants achieving a CLASI-50 response
Proportion of participants achieving a Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) response of at least 50% (CLASI-50). Participants achieve a CLASI-50 response if they have a ≥50% decrease from baseline in CLASI-A total score. CLASI-A scores range from 0 to 70, with higher scores indicating greater cutaneous lupus disease activity.
Time frame: Weeks 12, 16, and 24
Proportion of Participants Achieving a CLASI-A Total Score of 0 to 3
Proportion of participants achieving a CLASI-A total score of 0 to 3. Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) scores range from 0 to 70, with higher scores indicating greater cutaneous lupus disease activity.
Time frame: Weeks 12, 16, and 24
Proportion of Participants Achieving a Cutaneous Lupus Activity-Investigator's Global Assessment-Revised (CLA-IGA-R) Erythema Score of 0 or 1
Proportion of participants achieving a CLA-IGA-R Erythema score of 0 (clear) or 1 (almost clear). Scores range from 0 to 4, with lower scores indicating less disease activity.
Time frame: Weeks 12, 16, and Week 24
Percent Change From Baseline in CLASI-A Total Score
Percent change from baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) total score. CLASI-A scores range from 0 to 70, with higher scores indicating greater cutaneous lupus disease activity. A decrease from baseline indicates improvement.
Time frame: Weeks 12, 16, and 24
Proportion of Participants Achieving a CLA-IGA-R Mucous Membrane, Edema, and Scale/Hypertrophy (OMC) Score of 0 or 1
Proportion of participants achieving a CLA-IGA-R OMC score of 0 (clear) or 1 (almost clear). Scores range from 0 to 4, with lower scores indicating less disease activity
Time frame: Weeks 12, 16, and Week 24
Time to First CLASI Response
Time from baseline to first achievement of a protocol-defined CLASI response, including CLASI-70 (≥70% decrease from baseline in CLASI-A total score), CLASI-50 (≥50% decrease from baseline in CLASI-A total score), or a CLASI-A total score of 0 to 3
Time frame: Baseline through 24 weeks
Change From Baseline in Cutaneous Lupus Erythematosus Quality of Life (CLE-QoL) Total Score
Change from baseline in the Cutaneous Lupus Erythematosus Quality of Life total score. It is a 37-item patient-reported outcome measure that assesses the impact of cutaneous lupus erythematosus on quality of life across multiple domains. With higher scores indicating greater impairment in quality of life and a worse outcome.
Time frame: Weeks 12, 16, 24, and 52
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score
Change from baseline in DLQI total score. Scores range from 0 to 30, with higher scores indicating greater impairment in quality of life.
Time frame: Weeks 12, 16, 24, and 52
Change From Baseline in Patient Global Assessment of Skin Disease Activity (PtGA-Skin Disease Activity)
Change from baseline in PtGA-Skin Disease Activity score. The assessment uses a numeric rating scale ranging from 0 to 10. Higher scores indicate greater disease activity and worse symptoms.
Time frame: Weeks 12, 16, 24, and 52
Incidence of Serious Adverse Events (SAEs)
Number of participants experiencing at least one serious adverse event.
Time frame: Up to 52 Weeks
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Number of participants experiencing at least one treatment-emergent adverse event.
Time frame: Up to 52 Weeks
Proportion of Participants Achieving a ≥4-Point Reduction From Baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)
Proportion of participants with SLE at baseline achieving a reduction of at least 4 points from baseline in SLEDAI-2K score without change in lupus standard-of-care therapy and/or increase in oral corticosteroid dose. SLEDAI-2K scores range from 0 to 105, with higher scores indicating greater disease activity.
Time frame: Weeks 24 and 52
Proportion of Participants With SLE at Baseline Achieving Lupus Low Disease Activity State (LLDAS)
Proportion of participants with SLE at baseline achieving LLDAS
Time frame: Weeks 24 and 52
Plan to share: Undecided — No internal process at this time
No publications or documents are linked to this record.
Started Nov 2026 (actual). Primary completion is estimated for Apr 2030, 41 months after the start.
Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 10, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Afimetoran
Lupus Erythematosus, Cutaneous →
Beeline Medicines Corporation